

# William M Rosenberg Or W Rosenberg Or Wmc Rosenberg Or William Rosenberg Or Wm Rosenberg

List of Publications by Year in  
Descending Order

**Source:**

<https://exaly.com/author-pdf/3703767/william-m-rosenberg-or-w-rosenberg-or-wmc-rosenberg-or-william-rosenberg>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107  
papers

5,115  
citations

30  
h-index

71  
g-index

123  
ext. papers

6,023  
ext. citations

6.4  
avg, IF

5.15  
L-index

#	Paper	IF	Citations
107	Uncovering unsuspected advanced liver fibrosis in patients referred to alcohol nurse specialists using the ELF test. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 143	3	
106	Optimising referral pathways for patients with non-alcoholic fatty liver disease in the UK. <i>British Journal of Health Care Management</i> , <b>2021</b> , 27, 62-70	0.4	1
105	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00315	4.2	4
104	Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 1788-1802	4	1
103	The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 268	3	1
102	Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests. <i>BMJ Open</i> , <b>2021</b> , 11, e047786	3	1
101	A rational approach to improving titer in Escherichia coli-based cell-free protein synthesis reactions. <i>Biotechnology Progress</i> , <b>2021</b> , 37, e3062	2.8	1
100	Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 1435-1444	4	3
99	Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. <i>Hepatology Communications</i> , <b>2021</b> , 5, 786-797	6	3
98	Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. <i>Journal of Pediatrics</i> , <b>2021</b> , 239, 161-167.e5	3.6	2
97	Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF. <i>JHEP Reports</i> , <b>2021</b> , 3, 100328	10.3	1
96	Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 248-249	13.4	
95	Human Liver Memory CD8 T Cells Use Autophagy for Tissue Residence. <i>Cell Reports</i> , <b>2020</b> , 30, 687-698.e6	60.6	30
94	Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , <b>2020</b> , 73, 217-218	13.4	1
93	Detection, stratification and treatment of hepatitis C-positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 987-995	3.4	6
92	Treating prisoners with hepatitis C: should we do it and how? <b>2020</b> , 125-131		
91	Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 109-133	5.6	39

90	Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment. <i>Clinical Medicine</i> , <b>2020</b> , 20, 313-318	1.9	4
89	Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1580-1581	13.4	1
88	A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease. <i>Annals of Clinical Biochemistry</i> , <b>2020</b> , 57, 36-43	2.2	0
87	The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 104	3	0
86	The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 204-214	6.1	11
85	Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: a rapid-realist review. <i>BMC Health Services Research</i> , <b>2019</b> , 19, 152	2.9	12
84	Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 371-378	13.4	141
83	Epitope Presentation of Dengue Viral Envelope Glycoprotein Domain III on Hepatitis B Core Protein Virus-Like Particles Produced in. <i>Frontiers in Plant Science</i> , <b>2019</b> , 10, 455	6.2	13
82	Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , <b>2019</b> , 19, 122	3	36
81	Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. <i>Liver International</i> , <b>2019</b> , 39, 2052-2060	7.9	27
80	FRI-132-In vitro modulation by TLR8 agonist GS-9688 of multiple regulatory cell types in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e445	13.4	2
79	PS-078-A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e50-e51	13.4	9
78	Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. <i>European Journal of Clinical Investigation</i> , <b>2019</b> , 49, e13088	4.6	7
77	Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. <i>journal of applied laboratory medicine, The</i> , <b>2019</b> , 3, 815-826	2	14
76	Comparison and correlation of fibrosis stage assessment by collagen proportionate area (CPA) and the ELF panel in patients with chronic liver disease. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1001-1007	3.3	5
75	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. <i>Hepatology</i> , <b>2018</b> , 67, 2113-2126	11.2	18
74	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. <i>Liver International</i> , <b>2018</b> , 38, 1459-1467	7.9	21
73	A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles. <i>Vaccine</i> , <b>2018</b> , 36, 873-880	4.1	22

72	Applying Unique Molecular Identifiers in Next Generation Sequencing Reveals a Constrained Viral Quasispecies Evolution under Cross-Reactive Antibody Pressure Targeting Long Alpha Helix of Hemagglutinin. <i>Viruses</i> , <b>2018</b> , 10,	6.2	4
71	Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. <i>Programme Grants for Applied Research</i> , <b>2018</b> , 6, 1-528	1.5	3
70	The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , <b>2018</b> , 79, 694-699	0.8	8
69	A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. <i>Hepatology Communications</i> , <b>2018</b> , 2, 893-905	6	32
68	A Rapid and Robust Diagnostic for Liver Fibrosis Using a Multichannel Polymer Sensor Array. <i>Advanced Materials</i> , <b>2018</b> , 30, e1800634	24	44
67	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. <i>Liver International</i> , <b>2017</b> , 37, 1554-1561	7.9	39
66	T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System. <i>Journal of Immunology</i> , <b>2017</b> , 198, 1172-1182	5.3	28
65	Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates. <i>BMC Biotechnology</i> , <b>2017</b> , 17, 79	3.5	19
64	Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. <i>Journal of Clinical Gastroenterology</i> , <b>2017</b> , 51, 268-277	3	7
63	Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study. <i>Gastroenterology</i> , <b>2017</b> , 152, S1061	13.3	3
62	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , <b>2017</b> , 17, 603	4.1	10
61	The Enhanced Liver Fibrosis (ELF) Panel: Analyte Stability Under Common Sample Storage Conditions Used in Clinical Practice. <i>journal of applied laboratory medicine, The</i> , <b>2017</b> , 1, 720-728	2	5
60	Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 213, 1079-86	7	13
59	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155967	3.7	19
58	Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV. <i>Aids</i> , <b>2016</b> , 30, 723-9	3.5	8
57	Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 72, 274-80	3.1	4
56	Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. <i>Journal of Clinical Virology</i> , <b>2015</b> , 66, 33-7	14.5	23
55	Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosis. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 159-69	0.7	27

54	IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. <i>SpringerPlus</i> , <b>2015</b> , 4, 357		7
53	Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. <i>Hepatology</i> , <b>2015</b> , 62, 188-97	11.2	76
52	Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120751	3.7	73
51	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2608-17	59.2	613
50	Equilibrium contrast-enhanced CT imaging to evaluate hepatic fibrosis: initial validation by comparison with histopathologic sampling. <i>Radiology</i> , <b>2015</b> , 275, 136-43	20.5	52
49	Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure. <i>Antiviral Research</i> , <b>2014</b> , 105, 112-7	10.8	10
48	The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 420-7	2.4	28
47	Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts. <i>BMJ Open</i> , <b>2014</b> , 4, e004837	3	19
46	Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. <i>BMC Gastroenterology</i> , <b>2014</b> , 14, 137	3	28
45	Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon?. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 940-1	2.4	4
44	Complexities of HCV management in the new era of direct-acting antiviral agents. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2014</b> , 107, 17-9	2.7	5
43	Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. <i>Journal of Clinical Gastroenterology</i> , <b>2014</b> , 48, 370-6	3	19
42	Treatment decisions and contemporary versus pending treatments for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2013</b> , 10, 713-28	24.2	16
41	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2013</b> , 57, 103-11	11.2	81
40	The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. <i>PLoS Pathogens</i> , <b>2013</b> , 9, e1003208	7.6	135
39	The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 951-60	11.6	30
38	Predicted effects of treatment for HCV infection vary among European countries. <i>Gastroenterology</i> , <b>2012</b> , 143, 974-85.e14	13.3	98
37	Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. <i>PLoS ONE</i> , <b>2012</b> , 7, e51906	3.7	23

36	Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon $\alpha$ monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 543-50	2.2	5
35	Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. <i>PLoS ONE</i> , <b>2012</b> , 7, e47648	3.7	203
34	The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI). <i>PLoS ONE</i> , <b>2012</b> , 7, e50965	3.7	12
33	Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 38-44	13.4	44
32	A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 150-5	6.9	71
31	Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. <i>Gut</i> , <b>2010</b> , 59, 1245-51	19.2	212
30	Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. <i>BMC Gastroenterology</i> , <b>2010</b> , 10, 103	3	92
29	Psychosocial aspects of DNA testing for hereditary hemochromatosis in at-risk individuals: a systematic review. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2009</b> , 13, 7-14	1.6	12
28	Health outcomes following liver function testing in primary care: a retrospective cohort study. <i>Family Practice</i> , <b>2009</b> , 26, 251-9	1.9	19
27	Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth <i>Onchocerca volvulus</i> , can directly bind and activate antigen-presenting cells. <i>Journal of Immunology</i> , <b>2009</b> , 182, 4005-16	5.3	31
26	Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. <i>Gastroenterology</i> , <b>2009</b> , 136, 160-7	13.3	195
25	Psychosocial Aspects of DNA Testing for Hereditary Hemochromatosis in At-Risk Individuals: A Systematic Review. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2009</b> , 090108090224061		
24	Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. <i>Hepatology</i> , <b>2008</b> , 47, 455-60	11.2	494
23	Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. <i>Hepatology</i> , <b>2008</b> , 48, 1549-57	11.2	135
22	Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE). <i>BMC Health Services Research</i> , <b>2007</b> , 7, 54	2.9	12
21	Haemochromatosis. <i>Medicine</i> , <b>2007</b> , 35, 89-92	0.6	4
20	Variation in hepatitis C services may lead to inequity of health-care provision: a survey of the organisation and delivery of services in the United Kingdom. <i>BMC Public Health</i> , <b>2006</b> , 6, 3	4.1	30
19	Performance of serum marker panels for liver fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 462-74	13.4	181

18	Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 149-55	13.4	12
17	Haemochromatosis: the need for an agreed case definition. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 911	13.4	5
16	Comparison of genotypic and phenotypic strategies for population screening in hemochromatosis: assessment of anxiety, depression, and perception of health. <i>Genetics in Medicine</i> , <b>2005</b> , 7, 550-6	8.1	19
15	CD44 isoform expression on colonic epithelium mediates lamina propria lymphocyte adhesion and is controlled by Th1 and Th2 cytokines. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2003</b> , 15, 1101-10	2.2	14
14	Diaries of evidence-based tutors: beyond 5 numbers needed to teach <i>Journal of Evaluation in Clinical Practice</i> , <b>2000</b> , 6, 149-54	2.5	3
13	Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. <i>Hepatology</i> , <b>1999</b> , 30, 1037-44	11.2	49
12	Rapid mapping of markers applying vectorette technology to YAC fragmentation allows easy assembly of a high-density STS bacterial clone contig spanning the markers D6S1260-D6S1918. <i>Mammalian Genome</i> , <b>1998</b> , 9, 220-5	3.2	1
11	More microsatellite markers around D6S105. <i>Molecular and Cellular Probes</i> , <b>1998</b> , 12, 181-4	3.3	
10	Evidence-based Medicine and Child Mental Health Services. <i>Children and Society</i> , <b>1997</b> , 11, 89-96	1.4	1
9	How to Use Overviews of Prevention Trials to Treat Individual Patients. <i>Cerebrovascular Diseases</i> , <b>1996</b> , 6, 34-40	3.2	3
8	An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide. <i>European Journal of Immunology</i> , <b>1996</b> , 26, 335-9	6.1	43
7	CD44v6 and CD44v3 expression in ulcerative colitis and Crohn's disease. <i>Lancet, The</i> , <b>1995</b> , 346, 256	40	1
6	Evidence based medicine: an approach to clinical problem-solving. <i>BMJ: British Medical Journal</i> , <b>1995</b> , 310, 1122-6		647
5	Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. <i>Nature</i> , <b>1994</b> , 369, 403-7	50.4	387
4	A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. <i>European Journal of Immunology</i> , <b>1993</b> , 23, 447-53	6.1	96
3	An antigen processing polymorphism revealed by HLA-B8-restricted cytotoxic T lymphocytes which does not correlate with TAP gene polymorphism. <i>European Journal of Immunology</i> , <b>1993</b> , 23, 1999-2004	6.1	27
2	Assessments of hepatitis B virus-like particles and Crm197 as carrier proteins in melioidosis glycoconjugate vaccines		1
1	Management of HCV in Patients with Psychiatric Comorbidity	58-60	

